Novartis is in Li Zhenfu.

Novartis is a global leader in the pharmaceutical and consumer health care industries. Headquartered in Basel, Switzerland, Novartis has a global business in more than 40 countries and regions, with about 8 1400 employees. In 2007, Novartis's global sales reached $39.8 billion. Among the major pharmaceutical companies in the world, Novartis is the only one that keeps ahead in four areas: drugs, generic drugs, vaccines and diagnostic reagents, and consumer health care. The six drugs developed by the company won the Prix Galien Award, which is known as the Nobel Prize in pharmaceutical industry. 201065438+1October 8th, Novartis China officially announced that Yi Min succeeded Li Zhenfu as the president of Novartis China. Novartis also explained Li Zhenfu's whereabouts: "At the beginning of last year, Mr. Li Zhenfu expressed his hope to leave the company and go to China to develop his career." And further affirmed Li Zhenfu's contribution to Novartis. "Mr. Li Zhenfu joined Novartis in June 2004 and made great contributions to the growth and expansion of the company's business in China."

China headquarters of Novartis was established in 1997, but what really brought greater significance to Novartis was in 2004. For Novartis, who has just entered the China market, it seems to be a boon for Li Zhenfu, who knows the China market, has a good government background and overseas background, and is familiar with the operating rules of foreign companies. And Li Zhenfu also proved his significance to Novartis with his actions.

Li Zhenfu handed over a beautiful "report card" to Novartis in the first year. In 2004, China District of Novartis grew by 36.3%, of which the growth rate of drugs was 39. 1%, which was much higher than the global growth rate of Novartis and nearly three times that of the global growth rate.

Li Zhenfu attributed this achievement to the team's "localization" and understanding of the China market. Li Zhenfu said in an interview with the media: "Whether in the pharmaceutical industry or other industries, we are the most thoroughly localized one. I am an out-and-out Beijinger, so we have a full understanding of China and we fully respect China culture. "

Li Zhenfu has its own set of ideas on how to develop Novartis, and the embodiment of this idea in China lies in its "close" cooperation with the China municipal government. Even Queyranne, the newly appointed chairman of Novartis Pharmaceutical Greater China, admitted: "In terms of cooperation with the China government, Novartis has gone further than other multinational companies."

A series of "generous" government investments by Novartis in China have also won many opportunities for Novartis. Previously, when influenza A (H 1N 1) was prevalent, Novartis, as the first company to develop influenza A vaccine, made a lot of gains in cooperation with the China municipal government. At present, Novartis, as a "big family" in the pharmaceutical industry, has benefited a lot from the ongoing medical reform in China.